Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
RetinAI logo — Improving R&D of first-in-human drug candidates in pharma. S...

RetinAI

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.

Founded 2017 Switzerland Bern, Switzerland 43 employees Series B Total: $15.14M AI, Computing +3

General Information

Company Name RetinAI
Founded Year 2017
Location Switzerland Bern, Switzerland
Employees 43
Industries AI, Computing, Health Care +2
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with RetinAI. To contact RetinAI, visit retinai.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RetinAI compare?

A PDF of RetinAI and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RetinAI soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RetinAI

RetinAI is a Swiss & US-based software company focused on improving and supporting R&D of first-in-human drug candidates, supercharging management and oversight of clinical trials, and enabling the research needed to elevate the quality of care on patients with eye diseases. The company's slogan "Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care." succinctly encapsulates its mission. Founded in 2017, RetinAI operates in the AI, Computing, Health Care, Information Technology, and Machine Learning industries, with its headquarters in Switzerland. The company's fundamental belief is that in the future, every patient will use drugs alongside a digital application that will enable them and their physicians to better assess the right drug, in the right amount and the right frequency for patients. By building tools to collect, analyze, and organize health data, RetinAI is making strides towards this goal. Notably, the company secured a Series B investment on 16 October 2024. Although the specific investors of this round are not mentioned, this latest investment signifies a significant milestone in the company's journey towards shaping the future of healthcare and pharmaceuticals.

Business keywords: medical image analysis, med-tech, ophthalmology, optical coherence tomography, Fundus Image Photography, Retinal Angiography, age-related macular degeneration, diabetic retinopathy, glaucoma, Multiple Sclerosis, alzheimer, parkinson, digital health

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Fr.6.73M 4
Verve Ventures
Verve Ventures, Zürcher Kantonal Bank +2
16 Oct 2024
Series A Fr.5.65M 5
Verve Ventures Matterwave Ventures b2venture
Verve Ventures, Matterwave Ventures +3
02 May 2024
Seed Round Fr.2.30M 2
Verve Ventures Matterwave Ventures
Verve Ventures, Matterwave Ventures
11 Jun 2019
Grant Undisclosed 1
Eurostars
19 Mar 2019
Seed Round Fr.300.00K 1
Venture Kick
Venture Kick
15 Dec 2017
Pre Seed Round Fr.130.00K 1
Venture Kick
Venture Kick
06 Dec 2017
Grant Fr.20.00K 1
Venture Kick
Venture Kick
12 Jul 2017
Grant Fr.10.00K 1
Venture Kick
Venture Kick
28 Feb 2017

RetinAI Alternatives & Competitors

View All Alternatives
RetinAI vs
EyeCheckup - early diagnosis
EyeCheckup - early diagnosis United Kingdom

EyeCheckup is an early diagnosis system for preventing vision loss using artificial intelligence.

Seed
4 employees
AI, Health Care
Compare RetinAI vs EyeCheckup - early diagnosis
RetinAI vs
eye2you
eye2you Germany

Eye care everywhere

Pre-Seed
2 employees
AI, Digital Health
Compare RetinAI vs eye2you
RetinAI vs
EyRIS
EyRIS Singapore

Revolutionizing the detection of chronic diseases

14 employees
AI, Health Care
View all alternatives

FAQ About RetinAI

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.
RetinAI was founded in 2017.
RetinAI is headquartered in Bern, Switzerland.
RetinAI operates in AI, Computing, Health Care, Information Technology and Machine Learning. Its work centres on medical image analysis, med-tech, ophthalmology and optical coherence tomography.
RetinAI has approximately 43 employees.
RetinAI has completed 8 funding rounds, raising a total of $15.14M. The latest funding stage is Series B.
Top alternatives and competitors to RetinAI include EyeCheckup - early diagnosis, eye2you, EyRIS, Spect, MONA Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RetinAI and EyeCheckup - early diagnosis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RetinAI, https://bouncewatch.com/company/retinai, updated 24 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes